- Federal regulators have granted expedited approval to Eli Lilly's new orforglipron weight-loss pill, which will be branded as Foundayo and is expected to begin shipping on Monday.
- Foundayo is a GLP-1 drug that mimics a natural hormone to control appetite and feelings of fullness, similar to existing injectable medications.
- The company said people with insurance may be able to get the drug starting at $25 per month with a Lilly discount card. Prices for people paying cash will range between $149 per month to $349 per month, depending on the dose.
- Clinical trials showed participants on the highest dose of orforglipron lost an average of 11.2% of their body weight, 25 pounds on average, over 16 months, alongside improvements in waist circumference, blood pressure, and cholesterol levels.
- In a clinical trial of more than 3,000 adults, both the Lilly and Novo Nordisk pills resulted in less weight loss than the average achieved with Lilly’s injectable Zepbound, which results in a 21% average weight loss, or Novo Nordisk’s injectable Wegovy, which averages about 15%.
IN FULL
